Medicine and Dentistry
Chemoradiotherapy
69%
Esophageal Squamous Cell Carcinoma
65%
Epidermal Growth Factor Receptor
65%
Lung Cancer
58%
Lung Adenocarcinoma
53%
Radiation Therapy
52%
Intensity Modulated Radiation Therapy
49%
Multidrug Resistant Tuberculosis
32%
Clinical Stage
25%
Patient Compliance
19%
Small Cell Lung Cancer
18%
Disease
18%
Cisplatin
18%
Tyrosine-Kinase Inhibitor
17%
Prevalence
17%
Case-Control Study
16%
Drug Sensitivity
16%
Clear Cell Renal Cell Carcinoma
16%
Ex Vivo
16%
Squamous Cell Carcinoma
16%
Adenocarcinoma
16%
Astigmatism
16%
Corneal Topography
16%
Radiation Therapy Techniques
16%
Conformal Radiotherapy
16%
Mixed Infection
16%
Angiotensin Receptor Antagonist
16%
Circulating Tumor Cell
16%
ACE Inhibitor
16%
Protionamide
16%
Lipocortin 2
16%
Pterygium
16%
Carboplatin
16%
Lung Tuberculosis
16%
Acinetobacter Calcoaceticus
16%
Esophagectomy
16%
Bacteremia
16%
Acinetobacter Baumannii
16%
Latent Tuberculosis
16%
Tuberculosis
16%
Epidermal Growth Factor Receptor Kinase Inhibitor
16%
Nephrotoxicity
16%
Annexin
16%
Hazard Ratio
14%
Real-Time Polymerase Chain Reaction
13%
Proportional Hazards Model
13%
Visual Acuity
12%
Overall Survival
11%
Odds Ratio
11%
Cancer Registry
11%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Lung Cancer
74%
Lung Adenocarcinoma
60%
Chemoradiation Therapy
53%
Esophageal Squamous Cell Carcinoma
48%
Non Small Cell Lung Cancer
48%
Cisplatin
34%
Tuberculosis
32%
Case-Control Study
32%
Mycobacterium Tuberculosis
28%
Lung Tuberculosis
26%
Protein Tyrosine Kinase Inhibitor
21%
Neoplasm
19%
Small Cell Lung Cancer
18%
Prevalence
17%
Agar
16%
Urogenital Tuberculosis
16%
Dipeptidyl Carboxypeptidase Inhibitor
16%
Oncoprotein
16%
Angiotensin Receptor Antagonist
16%
Aromatic Hydrocarbon Receptor
16%
Latent Tuberculosis
16%
Squamous Cell Carcinoma
16%
Mixed Infection
16%
Human Papillomavirus
16%
Chloramphenicol
16%
Prothionamide
16%
Nephrotoxicity
16%
Epidermal Growth Factor Receptor Kinase Inhibitor
16%
Hypoxia Inducible Factor 1
16%
Multi-Drug-Resistant Tuberculosis
16%
Cucurbitacin
16%
Bacteremia
16%
Hemodialysis
16%
Uridine Diphosphate
16%
Acinetobacter Baumannii
16%
Antiproliferative Activity
16%
Acinetobacter Calcoaceticus
16%
Adenocarcinoma
16%
Carboplatin
16%
End Stage Renal Disease
15%
Chemotherapy
10%
Drug Resistance
9%
Overall Survival
8%
Infection
8%
Cancer Registry
8%
Mortality Rate
8%
Isoniazid
8%
Chronic Obstructive Lung Disease
7%
Comorbidity
7%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
41%
Cancer Cell
34%
Cisplatin
21%
Drug Resistance
21%
Wart Virus
16%
Drug Sensitivity
16%
MicroRNA
16%
Cell Migration
16%
Immunoglobulin Domain
16%
Polymerase Chain Reaction
16%
Hypoxia Inducible Factor 1
16%
Mycobacterium Tuberculosis
16%
Uridine Diphosphate
16%
Aryl Hydrocarbon Receptor
16%
Autophagy
16%
Case-Control Study
16%
Immunofluorescence
10%
Allele
9%
Genotyping
8%
Drug Fatality
8%
Mortality Rate
8%
Retrospective Study
8%
Cell Proliferation
7%
Messenger RNA
6%
Overall Survival
6%
Cadherin
5%
RNA
5%
Titer
5%
Homeobox Protein Nkx 2.1
5%
Ectopic Expression
5%
Real-Time Polymerase Chain Reaction
5%
Protein Expression
5%
Solution and Solubility
5%
Drug Screening
5%
Tumor Spheroid
5%
Untranslated Region
5%
Cell Expansion
5%
Neural Cell Adhesion Molecule
5%
Adenosine Triphosphate
5%
Epithelial Cell Adhesion Molecule
5%
Non-Coding RNA
5%
Synaptophysin
5%
Actin
5%
